1. Early patient and graft survival are excellent after liver transplantati
on.
2. The focus must be on reducing toxicity associated with long-term immunos
uppression.
3. Available new drugs offer the potential to reduce toxicity by combinatio
n therapy or replacement of toxic agents.
4. Individual patient immunosuppressive protocols should be developed.
5. Drug interactions are common and the source of significant morbidity.